Yep, they are getting stretched thin. They couldn't even organise a webcast for the AGM because of "the logistics involved for a small biotech of SPL's size." There is no doubt in my mind that they are limited by their size, and this is the main reason for their slow pace in pushing some things. And there is no doubt that their technology and everything they have to offer the medical world would be expedited in larger hands, and on a grander scale, which is better for everybody given the potential. Otherwise they are in danger of missing the boat completely. What they have is massive, and it is already worth billions to any big pharma for the re-patent and market share protection alone, not to mention the BV market and all the other "optionality" of DEP. Whatever happens today, and I'm not expecting much, the visit is a ringing endorsement and a reminder to be patient and not shaken. Our time will come.
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
